Citadel Advisors
ECYT

Citadel Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Citadel Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-95,100
Closed -$1.69M – 10200
2018
Q3 		$1.69M Buy
95,100
+12,900
+16% +$221K ﹤0.01% 4674
2018
Q2 		$1.13M Sell
82,200
-21,500
-21% -$255K ﹤0.01% 5000
2018
Q1 		$943K Buy
103,700
+66,900
+182% +$369K ﹤0.01% 4905
2017
Q4 		$158K Buy
+36,800
New +$175K ﹤0.01% 7252
2016
Q2 		– Sell
-15,700
Closed -$49K – 7739
2016
Q1 		$49K Buy
15,700
+6,000
+62% +$19.6K ﹤0.01% 6256
2015
Q4 		$39K Sell
9,700
-1,500
-13% -$6.91K ﹤0.01% 7498
2015
Q3 		$51K Buy
11,200
+3,300
+42% +$17.3K ﹤0.01% 7572
2015
Q2 		$41K Sell
7,900
-3,800
-32% -$22.8K ﹤0.01% 7801
2015
Q1 		$73K Sell
11,700
-1,500
-11% -$8.66K ﹤0.01% 7122
2014
Q4 		$83K Sell
13,200
-19,900
-60% -$121K ﹤0.01% 6803
2014
Q3 		$201K Buy
33,100
+1,900
+6% +$13K ﹤0.01% 5722
2014
Q2 		$206K Sell
31,200
-20,500
-40% -$231K ﹤0.01% 5537
2014
Q1 		$1.23M Buy
51,700
+39,100
+310% +$567K ﹤0.01% 3177
2013
Q4 		$135K Buy
+12,600
New +$139K ﹤0.01% 5373

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Citadel Advisors's ECYT Position: Q4 2018 in Review

Citadel Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 1,361,949 shares — an estimated $24.2M sold.

Citadel Advisors first reported a position in ECYT in Q4 2013 and held it in 18 quarters. The position peaked at $27.6M in Q2 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Citadel Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Citadel Advisors sold 1,361,949 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $24.2M.
  • Citadel Advisors first reported a position in Endocyte, Inc. Common Stock in Q4 2013 and held it in 18 quarters.
  • Citadel Advisors's Endocyte, Inc. Common Stock position peaked at $27.6M in Q2 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.